Back

Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Dennis Jensen

University Heart Center, Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail
One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy
Doctor G. Bonacchi (Florence, IT)
Abstract Slides
Presentation thumbnail
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides
Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
Doctor S. Hoss (Petah Tikva, IL)
Abstract Slides
Presentation thumbnail
Impact of mavacamten on left atrial remodeling in obstructive hypertrophic cardiomyopathy: data from 3 portuguese centers
Doctor I. Miranda (Amadora, PT)
Abstract Slides

Access the full session

Session thumbnail
Cardiac myosin inhibition in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
31 August 2019
thumbnail
Congress Presentation
Sacubitril/Valsartan efficacy on functional, laboratory, echocardiographic parameters: a real-world study
29 June 2021
thumbnail
Congress Presentation
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
2 September 2024
thumbnail
Congress Presentation
Clinical burden of obstructive hypertrophic cardiomyopathy: insights from a nationwide study in France
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources